382 related articles for article (PubMed ID: 10352162)
1. Transplantation of anergic histoincompatible bone marrow allografts.
Guinan EC; Boussiotis VA; Neuberg D; Brennan LL; Hirano N; Nadler LM; Gribben JG
N Engl J Med; 1999 Jun; 340(22):1704-14. PubMed ID: 10352162
[TBL] [Abstract][Full Text] [Related]
2. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
3. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA
Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644
[TBL] [Abstract][Full Text] [Related]
4. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.
Aversa F; Tabilio A; Velardi A; Cunningham I; Terenzi A; Falzetti F; Ruggeri L; Barbabietola G; Aristei C; Latini P; Reisner Y; Martelli MF
N Engl J Med; 1998 Oct; 339(17):1186-93. PubMed ID: 9780338
[TBL] [Abstract][Full Text] [Related]
5. Transplantation of anergic histoincompatible bone marrow cells.
de Carvalho Bittencourt M; Tiberghien P; Saas P
N Engl J Med; 1999 Sep; 341(14):1081-2. PubMed ID: 10507928
[No Abstract] [Full Text] [Related]
6. Preventing allograft rejection with CTLA4IG: effect of donor-specific transfusion route or timing.
Bolling SF; Lin H; Wei RQ; Turka LA
J Heart Lung Transplant; 1996 Sep; 15(9):928-35. PubMed ID: 8889989
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of pretransplant donor anti-recipient cytotoxic and helper T lymphocyte responses as correlates of acute graft-vs.-host disease and survival after unrelated marrow transplantation.
Pei J; Martin PJ; Longton G; Masewicz S; Mickelson E; Petersdorf E; Anasetti C; Hansen J
Biol Blood Marrow Transplant; 1997 Aug; 3(3):142-9. PubMed ID: 9310191
[TBL] [Abstract][Full Text] [Related]
8. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA
J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249
[TBL] [Abstract][Full Text] [Related]
9. Flt3-L augments the engraftment of donor-derived bone marrow cells when combined with sublethal irradiation and costimulatory (CD28/B7 and CD40/CD40L) blockade.
Woodward JE; Salam A; Logar AJ; Schaefer AT; Rao AS
Cell Transplant; 2002; 11(2):147-59. PubMed ID: 12099638
[TBL] [Abstract][Full Text] [Related]
10. Helper T-lymphocyte precursor frequency predicts the occurrence of graft-versus-host disease and disease relapse after allogeneic bone marrow transplantation from HLA-identical siblings.
Leung AY; Kwok J; Lie AK; Chen P; Chen FE; Liang R
Haematologica; 2001 Jun; 86(6):652-6. PubMed ID: 11418376
[TBL] [Abstract][Full Text] [Related]
11. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease.
Georgantas RW; Bohana-Kashtan O; Civin CI
Transplantation; 2006 Aug; 82(4):471-8. PubMed ID: 16926590
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
15. Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Vallera DA
Blood; 1995 May; 85(9):2607-18. PubMed ID: 7537122
[TBL] [Abstract][Full Text] [Related]
16. Induction of alloantigen-specific T cell tolerance through the treatment of human T lymphocytes with wortmannin.
Taub DD; Murphy WJ; Asai O; Fenton RG; Peltz G; Key ML; Turcovski-Corrales S; Longo DL
J Immunol; 1997 Mar; 158(6):2745-55. PubMed ID: 9058809
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
[TBL] [Abstract][Full Text] [Related]
18. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
[TBL] [Abstract][Full Text] [Related]
19. Immunomonitoring of graft-versus-host minor histocompatibility antigen correlates with graft-versus-host disease and absence of relapse after graft.
Laurin D; Hannani D; Pernollet M; Moine A; Plumas J; Bensa JC; Cahn JY; Garban F
Transfusion; 2010 Feb; 50(2):418-28. PubMed ID: 19843288
[TBL] [Abstract][Full Text] [Related]
20. Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade.
Foster RD; Pham S; Li S; Aitouche A
Transplantation; 2003 Sep; 76(6):988-94. PubMed ID: 14508367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
